Phcog.Net logo
Submit

BROWSE ALL JOURNALS

    SEE ALL 6 JOURNALS
    Journal of Pharmacology and PharmacotherapeuticsNOW IN
    Article

    Recurrence of atrial fibrillation after switching from brand to generic atenolol

    Luca Gallelli1★, Francesca Maida1, Orietta Staltari1, Pierandrea Rende1, Emilio Russo1, Benedetto Caroleo1★ Corresponding author

    1. 1Giovambattista De Sarro Department of Health Science, University of Catanzaro, Catanzaro, Italy.

    CORRESPONDENCE

    Luca Gallelli

    Giovambattista De Sarro Department of Health Science, University of Catanzaro, Catanzaro, Italy.

    gallelli@unicz.it

    Received: 23-01-2014; Revised: 31-05-2014; Accepted: 28-06-2014.

    Volume 6, Issue 1 · pp. 158–160 · PUBLISHED 2014 · DOI: 10.4103/0976-500X.149146

    View on J Pharmacol. Pharmacother. original site ↗

    ABSTRACT

    Beta blockers are the initial treatment for rate control of supraventricular tachyarrhythmia in patients without a history of myocardial infarction or left ventricular dysfunction. In this article we report the recurrence of atrial fibrillation after switching to the generic formulation of atenolol.

    KEYWORDS

    Open in new tab

    REFERENCES

    As published

    Showing references and in-text citations exactly as published.

      Cite this article

      SELECT FORMAT

      Gallelli, L., Maida, F., Staltari, O., Rende, P., Russo, E., & Caroleo, B. (2014). Recurrence of atrial fibrillation after switching from brand to generic atenolol. Journal of Pharmacology and Pharmacotherapeutics, 6(1), 158–160. https://doi.org/10.4103/0976-500X.149146